Dear All,

Almost ten years ago, we were founded by the Multidisciplinary Association for Psychedelic Studies (“MAPS”) to further the development and treatment of mental health with psychedelic assisted therapy. Starting in 2014, we accepted that challenge and are proud of the significant progress we have made to date. Most recently, our Phase 3 clinical trials studying investigational MDMA-assisted therapy for PTSD were completed and the data has been submitted to the FDA.

To reflect this evolution in our journey, MAPS Public Benefit Corporation has rebranded to Lykos Therapeutics. We selected a new name, Lykos or wolf in Greek, to represent the qualities—bravery, courage, loyalty and intelligence—that resonate with our company. Along with the name change, the new visual identity represents the overlap of innovative science combined with focus on the whole person.

While our name is changing, our commitment to public benefit is not. As Lykos, we are committed to continue building on the legacy of MAPS and to making a real difference in patients' lives by transforming mental health care. As a public benefit corporation, we have a unique responsibility to prioritize the impact we have on society. Our North star is to fundamentally change how the healthcare system holistically treats people with mental health conditions. We are working to articulate what it means to be a leading public benefit organization in the pharmaceutical space. We have started by creating four tenets to guide our focus which include:

1. We are focused on addressing unmet mental health needs.
2. We will work to prioritize access.
3. We intend to have ethical, inclusive and sustainable operations.
4. We aim to have equitable and inclusive management of science, data, and intellectual property rights

We will be sharing more detail on our corporate website soon. This will include how we are delivering on public benefit today, and how we plan to continue doing as we embark on the exciting challenges and adventures ahead of us.

Thank you,

Amy Emerson
CEO
Lykos Therapeutics